Dr Reddys Laboratories Ltd (DRREDDY) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 734514, "name": "Dr Reddy's Labs", "stock_name": "Dr Reddy's Labs", "full_name": "Dr Reddys Laboratories Ltd", "name_url": "stocks-analysis/dr-reddy-s-labs", "exchange": 0, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "1,241.15", "chg": -4, "chgp": "-0.32%", "dir": -1, "prev_price": "1,245.15", "mcapval": "102,722.00 Cr", "mcap": "Large Cap", "scripcode": "500124", "symbol": "DRREDDY", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE089A01031", "curr_date": "Feb 06", "curr_time": "", "bse_nse_vol": "13.44 lacs", "exc_status": "Active", "traded_date": "Feb 06, 2026", "traded_date_str": "2026 02 06", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Dr Reddys Laboratories Gains 1.87%: 3 Key Factors Driving the Week’s Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-gains-187-3-key-factors-driving-the-weeks-momentum-3826384", "imagepath": "", "date": "2026-02-07 15:10:07", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>2 Feb:</strong> Stock falls 2.96% amid broader market weakness</p>\n <p><strong>3 Feb:</strong> Opens with 7.33% gap up, hits intraday high of Rs 1,269.05</p>\n <p><strong>6 Feb:</strong> Technical momentum shifts to mildly bearish with 0.40% gain</p>\n <p><strong>Week Close:</strong> Rs.1,241.15 (+1.87%) vs Sensex +1.51%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,218.40</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,2..." }, { "title": "Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-technical-momentum-shifts-amid-mixed-market-signals-3823628", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/DrReddysLaborat_technicaldot_3823628.png", "date": "2026-02-06 08:02:02", "description": "Dr Reddys Laboratories Ltd has experienced a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day gain of 0.40%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and volume-based metrics. This analysis delves into the recent technical parameter changes and their implications for investors navigating the Pharmaceuticals & Biotechnology sector." }, { "title": "Dr Reddys Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-sell-3822356", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/DrReddysLaborat_mojoScore_3822356.png", "date": "2026-02-05 10:10:04", "description": "Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 February 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Performance and Institutional Shifts", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-performance-and-institutional-shifts-3821937", "imagepath": "", "date": "2026-02-05 09:20:56", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Significance of Nifty 50 Membership</strong></p>\n <p>Being part of the Nifty 50 index confers Dr Reddys Laboratories Ltd a significant stature in the Indian equity market. The index membership not only reflects the company’s large market capitalisation—currently standing at ₹1,03,577.63 crores—but also ensures heightened visibility among domestic and global institutional investors. This inclusion often results in increased liquidity and trading volumes, as index funds and ETFs tracking the Nifty 50 allocate capital accordingly.</p>\n <p>However, membership also brings scrutiny and expectations. Dr Reddys’ performance is closely monitored relative to the broader index and sector peers. Over the past year, the stock has delivered a 1.06% return, lagg..." }, { "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Performance and Institutional Shifts", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-performance-and-institutional-shifts-3820024", "imagepath": "", "date": "2026-02-04 09:20:53", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Significance of Nifty 50 Membership</strong></p>\n <p>Being part of the Nifty 50 index confers considerable prestige and liquidity advantages to Dr Reddys Laboratories Ltd. The index, representing the top 50 blue-chip companies listed on the National Stock Exchange of India, serves as a barometer for the Indian equity market. Inclusion ensures enhanced visibility among domestic and global institutional investors, index funds, and exchange-traded funds (ETFs) that track the benchmark.</p>\n <p>Dr Reddys’ market capitalisation stands at a robust ₹1,03,619.36 crores, categorising it firmly as a large-cap stock. This sizeable market cap underpins its continued presence in the index, despite recent relative underperformance compared to the broader Sensex..." }, { "title": "Dr Reddys Laboratories Ltd Opens Strong with 7.33% Gap Up Amid Positive Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-opens-strong-with-733-gap-up-amid-positive-market-sentiment-3817936", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/DrReddysLaborat_gapup_3817936.png", "date": "2026-02-03 09:57:00", "description": "Dr Reddys Laboratories Ltd witnessed a robust start to the trading session on 3 Feb 2026, opening with a significant gap up of 7.33%, reflecting positive market sentiment within the Pharmaceuticals & Biotechnology sector. The stock outperformed both its sector and the broader Sensex index, signalling renewed momentum after a brief period of decline." }, { "title": "Dr Reddys Laboratories Ltd Hits Intraday High with 3.56% Surge on 3 Feb 2026", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-high-with-356-surge-on-3-feb-2026-3817679", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/DrReddysLaborat_priceRelatedfactors_3817679.png", "date": "2026-02-03 09:41:54", "description": "Dr Reddys Laboratories Ltd demonstrated robust intraday performance on 3 Feb 2026, surging to an intraday high of Rs 1269.05, marking a 7.33% gain from the previous close. The stock outperformed its sector and broader market indices, reflecting notable trading momentum during the session." }, { "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Volatile Market Moves", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-volatile-market-moves-3817448", "imagepath": "", "date": "2026-02-03 09:23:13", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Significance of Nifty 50 Membership</strong></p>\n <p>Being part of the Nifty 50 index confers considerable advantages and responsibilities on Dr Reddys Laboratories Ltd. As one of the 50 largest and most liquid stocks on the National Stock Exchange of India, the company benefits from enhanced visibility among domestic and international investors. Index funds and exchange-traded funds (ETFs) tracking the Nifty 50 are mandated to hold shares of Dr Reddys Laboratories, ensuring a steady demand irrespective of short-term market fluctuations.</p>\n <p>This membership also subjects the stock to rigorous scrutiny, with performance often benchmarked against the broader index. Dr Reddys Laboratories’ market capitalisation currently stands at a substantial ₹..." }, { "title": "Dr Reddys Laboratories Ltd Faces Downgrade Amidst Mixed Market Performance and Nifty 50 Membership Significance", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-mixed-market-performance-and-nifty-50-membership-significance-3815891", "imagepath": "", "date": "2026-02-02 09:20:32", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Index Membership and Market Significance</strong></p>\n <p>As a key member of the Nifty 50, Dr Reddys Laboratories Ltd holds considerable influence on the benchmark’s overall performance, particularly within the Pharmaceuticals & Biotechnology sector. The company’s market capitalisation stands at a robust ₹99,149.91 crores, underscoring its stature as a large-cap stock. Its inclusion in the index not only attracts passive fund flows from index-tracking funds but also places it under the scrutiny of institutional investors who closely monitor sectoral and market-wide trends.</p>\n <p>However, the stock’s recent performance has been underwhelming relative to the Sensex and sector peers. Over the past year, Dr Reddys Laboratories has recorded a decline..." } ], "total": 466, "sid": "734514", "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "datetime": "02-Feb-2026", "details": "Schedule of Analyst meet", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome", "datetime": "27-Jan-2026", "details": "Transcript of earnings call conducted on January 21 2026", "source": "BSE" }, { "caption": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015", "datetime": "24-Jan-2026", "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 25", "dt": "2025-07-10", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24", "dt": "2024-10-28", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06", "dt": "2006-08-28", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

2 Feb: Stock falls 2.96% amid broader market weakness

3 Feb: Opens with 7.33% gap up, hits intraday high of Rs 1,269.05

6 Feb: Technical momentum shifts to mildly bearish with 0.40% gain

Week Close: Rs.1,241.15 (+1.87%) vs Sensex +1.51%

Read full news article

Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-02-06 08:02:02

Dr Reddys Laboratories Ltd has experienced a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day gain of 0.40%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and volume-based metrics. This analysis delves into the recent technical parameter changes and their implications for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Dr Reddys Laboratories Ltd is Rated Sell

2026-02-05 10:10:04

Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Performance and Institutional Shifts

2026-02-05 09:20:56

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers Dr Reddys Laboratories Ltd a significant stature in the Indian equity market. The index membership not only reflects the company’s large market capitalisation—currently standing at ₹1,03,577.63 crores—but also ensures heightened visibility among domestic and global institutional investors. This inclusion often results in increased liquidity and trading volumes, as index funds and ETFs tracking the Nifty 50 allocate capital accordingly.

However, membership also brings scrutiny and expectations. Dr Reddys’ performance is closely monitored relative to the broader index and sector peers. Over the past year, the stock has delivered a 1.06% return, lagg...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Performance and Institutional Shifts

2026-02-04 09:20:53

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable prestige and liquidity advantages to Dr Reddys Laboratories Ltd. The index, representing the top 50 blue-chip companies listed on the National Stock Exchange of India, serves as a barometer for the Indian equity market. Inclusion ensures enhanced visibility among domestic and global institutional investors, index funds, and exchange-traded funds (ETFs) that track the benchmark.

Dr Reddys’ market capitalisation stands at a robust ₹1,03,619.36 crores, categorising it firmly as a large-cap stock. This sizeable market cap underpins its continued presence in the index, despite recent relative underperformance compared to the broader Sensex...

Read full news article

Dr Reddys Laboratories Ltd Opens Strong with 7.33% Gap Up Amid Positive Market Sentiment

2026-02-03 09:57:00

Dr Reddys Laboratories Ltd witnessed a robust start to the trading session on 3 Feb 2026, opening with a significant gap up of 7.33%, reflecting positive market sentiment within the Pharmaceuticals & Biotechnology sector. The stock outperformed both its sector and the broader Sensex index, signalling renewed momentum after a brief period of decline.

Read full news article

Dr Reddys Laboratories Ltd Hits Intraday High with 3.56% Surge on 3 Feb 2026

2026-02-03 09:41:54

Dr Reddys Laboratories Ltd demonstrated robust intraday performance on 3 Feb 2026, surging to an intraday high of Rs 1269.05, marking a 7.33% gain from the previous close. The stock outperformed its sector and broader market indices, reflecting notable trading momentum during the session.

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Volatile Market Moves

2026-02-03 09:23:13

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable advantages and responsibilities on Dr Reddys Laboratories Ltd. As one of the 50 largest and most liquid stocks on the National Stock Exchange of India, the company benefits from enhanced visibility among domestic and international investors. Index funds and exchange-traded funds (ETFs) tracking the Nifty 50 are mandated to hold shares of Dr Reddys Laboratories, ensuring a steady demand irrespective of short-term market fluctuations.

This membership also subjects the stock to rigorous scrutiny, with performance often benchmarked against the broader index. Dr Reddys Laboratories’ market capitalisation currently stands at a substantial ₹...

Read full news article

Dr Reddys Laboratories Ltd Faces Downgrade Amidst Mixed Market Performance and Nifty 50 Membership Significance

2026-02-02 09:20:32

Index Membership and Market Significance

As a key member of the Nifty 50, Dr Reddys Laboratories Ltd holds considerable influence on the benchmark’s overall performance, particularly within the Pharmaceuticals & Biotechnology sector. The company’s market capitalisation stands at a robust ₹99,149.91 crores, underscoring its stature as a large-cap stock. Its inclusion in the index not only attracts passive fund flows from index-tracking funds but also places it under the scrutiny of institutional investors who closely monitor sectoral and market-wide trends.

However, the stock’s recent performance has been underwhelming relative to the Sensex and sector peers. Over the past year, Dr Reddys Laboratories has recorded a decline...

Read full news article

View All News